Orlando, FL, July 16, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- REMSleep Holdings, Inc. (OTC PINK: RMSL) and its principals are pleased to announce the company is moving forward to product production of the Deltawave CPAP interface and will be proceeding forward with packaging, instruction manual, etc. Finished product meets the company’s every expectation. Deltawave is designed to provide a maximum guard against irregular and/or inadequate breathing while trying to sleep.
REMSleep is confidant patients who choose Deltawave will be able to sleep with Deltawave eight hours, or as many hours each and every night as needed , and be able to sustain treatment permanently. CPAP patients who achieve successful compliance will require (1) Normal tidal volume (size of breath) (2) Normal inspiratory time (time it takes to breath in), (3) Normal expiratory time (time it takes to exhale), (4) Normal respiratory rate (14 breaths per minute) (5) Normal minute ventilation (total amount of air breathed in one minute), (6) No discomfort while wearing CPAP (especially as the night progresses).
After wearing Deltawave for 5 to 15 minutes, and/or before stage 1 sleep, the successfully compliant patient is completely relaxed to the point where breathing is being completely supported by Deltawave and the autonomic nervous system. The patient is exerting no external effort to breathe. This will simulate the status of breathing after the patient falls into deep sleep. When this is achieved the patient feels secure and easily progresses into sleep stages. When the patient wakes momentarily at any time during the night the patient quickly realizes breathing has been perfect and the patient quickly falls back to deep sleep.
REMSleep Holdings, Inc. was founded to design and manufacture devices and products for the treatment of sleep apnea and other respiratory conditions. With over 50 years of collective experience in CPAP therapy, the REMSleep team has extensive knowledge and understanding of CPAP and the challenges of patient compliance. REMSleep Holdings, Inc. has a new patent pending, innovative sleep apnea product that will meet multiple market needs and then be able to reach and address a large percentage of the patient population who continue to struggle with CPAP compliance.
Forward-looking statements
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words "may", "will", "should", "continue", "expect", "anticipate", "estimate", "believe", "intend", "plan" or "project" or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company's ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to obtain sufficient financing to execute the Company's business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company's public disclosure record on file with the relevant securities regulatory authorities. No information in this press release should be construed as any indication whatsoever of the Company's future revenues, results of operations or stock price. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.
Tom Wood
912-590-2001
Twood@remsleep.com